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Edited by Lukas HuberAbstract Survivin protein accomplishes two basic functions:
cell cycle regulation and control of apoptosis. It is only expressed
in G2/M phase and it inﬂuences rescue pathways in apoptosis-in-
duced cells. Overexpression of constitutive active c-H-ras in
HeLa, or induction of c-H-ras in a stable HeLaDiR cell line,
led to sustained survivin expression in all cell cycle phases and
even protected cells from drug induced apoptosis. siRNA-medi-
ated silencing of survivin reversed this protection. Here we link
the anti-apoptotic property of survivin to its cell cycle (in)depen-
dent regulation via the activity of oncogenic c-H-ras.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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In the past few years research on the inhibitor of apoptosis
protein (IAP) survivin has elucidated a variety of aspects con-
cerning regulation of microtubule dynamics [1,2], control of
mitosis and cell cycle [3–6], interaction with and control of apop-
totic machinery [6,7], pathways in cancer development [8] and its
potential as a new target in anticancer interventions [9,10].
Highly expressed during embryonic development, survivin is
not detectable in most diﬀerentiated tissues [11,12], with the
exception of primitive hematopoetic cells, T lymphocytes and
vascular endothelial cells [13]. Noticeable is its reexpression
in the majority of human tumors [12]. Moreover, detection
of high level expression provides prognostically relevant infor-
mation, as it is predictive of tumor progression as well as sig-
niﬁcantly shorter patient survival [14,15]. High expression
levels of survivin also correlate with an increased rate of tumor
recurrence and resistance to chemo- and radiotherapy [16,17].
Particularly this fact corroborates the theory, that regulation
of survivin signaling interactions may diﬀer in normal versusAbbreviations: IAP, inhibitor of apoptosis protein; DiR, dexametha-
sone inducible ras; Dex, dexamethasone
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doi:10.1016/j.febslet.2007.09.023cancer cells [18], supporting its aforementioned potential in
anticancer treatment. In ﬁrst experimental settings the inhibi-
tion of survivin expression by anti-sense or dominant-negative
mutants triggers apoptosis as well as defects in cell division
[9,10].
Oncogenic mutations in the ras gene are present in approx-
imately 30% of all human cancers [19]. Mutated, constitutive
activated RAS drives signaling pathways that block apoptosis
and enhance cell cycle [20]. The ras/survivin axis was described
as an oncogenic pathway that leads to upregulation of survivin
gene-expression [21].
In survivin biology two basic modes of operation – in mito-
sis as well as survival – are described [22]. Its role in mitosis
and the cell cycle periodicity is controlled on transcriptional
[23] and post-translational levels [24], which result in peak
expression at mitosis. In this phase survivin is found localised
at various components of the mitotic apparatus like centro-
somes, microtubules and midbodies [21,25].
An additional question in this context is how survivin
(de)regulation converges with its role in preventing apoptosis.
Survivin is supposed to interfere with the apoptotic machinery
by directly inhibiting caspases, cell death speciﬁc proteases, or
their activation [26,27]. A recently described mitochondrial
localisation of survivin in tumor cell lines has been linked to
apoptosis resistance and therefore enhanced tumorigenicity
[7]. Growing evidence indicates that survivin also acts in a cas-
pase-independent manner [28,29]. A central question to under-
stand the contribution of survivin to cancer development is its
cell cycle independent gene-expression, identiﬁed in various
cancers [30] and cell systems [21,31].
In the present work we characterised in a human carcinoma
cell line the ras/survivin axis [20,21] as a possible connection
between the anti-apoptosis property of survivin and its (de)reg-
ulated expression during the cell cycle, that entails an improve-
ment for survival and consequently might inﬂuence therapeutic
strategies.2. Materials and methods
2.1. Chemicals and antibodies
Anti-survivin (A-19) and anti-caspase 3 (H-277) were purchased
from Santa Cruz, anticleaved caspase 3 (9661) from Cell Signal-
ing, anti-p21ras from DAKO Diagnostics, anti-actin from Sigma.blished by Elsevier B.V. All rights reserved.
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from Calbiochem, Complete Protease Inhibitor Cocktail from Roche
Diagnostics, Lipofectamine 2000 from Invitrogen, propidium iodide,
RNaseA, L-mimosine, thymidine and nocodazole from Sigma.2.2. Cell culture and transfection
To obtain stable cell lines HeLa cells were transfected with a
MMTV-rasA construct, expressing a dexamethasone (Dex)-inducible
constitutive active, oncogenic mutation (V12) of the human c-H-ras
gene (dexamethasone inducible Ras; DiR) [32] together with a neo-
resistance gene by Lipofectamine 2000. Transfected HeLa cells were
selected with G418 (800 lg/ml) and Dex (1 lM) in RPMI supple-
mented with penicillin/streptomycin and 10% FCS. Individual clones
were isolated (HeLaDiR clones) and cultured in the presence or ab-
sence of Dex. For cell cycle arrest, growing cells were treated for
24 h with 1.5 lM nocodazole to arrest in G2/M, 400 lM mimosine
to arrest in G1 and 2 mM thymidine to arrest in G1/S.2.3. Western blotting, Northern blotting
Western blotting was performed as previously described [21]. Brieﬂy,
cells were harvested by scraping, washed twice in ice-cold PBS and
lysed in RIPAII. Lysates were sonicated, centrifuged at 12.000 · g
and supernatants were used as total cell lysates. Twenty micrograms
total protein was separated on SDS–PAGE. Northern blot analysis
of 10 lg total RNA was performed as described in [33].2.4. FACS analysis
After arresting cells as described in Section 2.2, cells were harvested
by trypsinisation and ﬁxed overnight in 70% ice-cold ethanol, washed
in PBS and resuspended in 1 ml PBS containing 5 lg/ml propidium io-
dide and 100 lg/ml RNaseA. Samples were incubated for 60 min at
37 C and placed at 4 C before ﬂow cytometry analysis. Samples were
analysed with a Becton Dickinson FACSCalibur system using CELL-
Quest software.2.5. Determination of apoptosis
The adequate time point for these experiments was determined in
untransfected, G1 arrested HeLa cells. After 18 h of mimosine treat-
ment, Doxorubicin was added in a time course up to 24 h and cells
were prepared for Western analysis of cleaved caspase 3. For transient
ectopic expression of human c-H-rasVal12 a plasmid construct with the
cDNA under control of the cytomegalovirus promoter (CMVras) [34]
was applied. HeLa cells were seeded into 24-well plates (4 · 105/well)
24 h before transient transfection (1 lg DNA/well, Lipofectamine
2000) with CMVras or pUC19 as vector control. 4 h after transfection,
cells were arrested in G2/M, G1 and in S for 24 h. For the last 8 h cells
were treated with Doxorubicin (4 lM). Cells were ﬁxed with 3% form-
aldehyde/PBS and DNA was stained with DAPI (1 lg/ml). As apopto-
tic marker condensed and fragmented nuclei were used. Per condition,
about 1000 cells were counted in randomly chosen microscopic ﬁelds
(Nikon Eclipse TE300 microscope, 60·).2.6. siRNA experiments
FITC labeled siRNA oligos (VBC-Genomics, Austria) were
described in [35]. Brieﬂy, the sequence of SRi-2 was GCGCCUG-
CACCCCGGAGCGTT and for scraSRi CAGUCGCGUUUGCG-
ACUGGTT and the respective inverse complementary sequences for
in vitro annealing. HeLa cells were seeded into 24-well plates
(2 · 105/well) 24 h before transient Lipofectamine 2000 transfection
with either 1 lg/well pUC19 as transfection control alone or together
with 2 lM of FITC labeled siRNA construct against survivin mRNA
(SRi-2). A FITC labeled, scrambled RNA construct (scraSRi) was
used as siRNA control. Transfection rate was determined by ﬂuores-
cence microscopy. Four hours after transfection cells were arrested
in G2/M for 24 h. For the last 8 h cells were treated with 4 lM Doxo-
rubicin. Cells were ﬁxed with 3% formaldehyde/PBS and DNA was
stained with DAPI. Per condition, 10 randomly chosen microscopic
ﬁelds were counted and apoptosis rate was determined. For determina-
tion of silenced survivin expression, HeLa cells were transiently trans-
fected with pUC19 alone or together with SRi-2 and scraSRi. 28 h
after transfection cell lysates were prepared for immunoblotting.3. Results
3.1. Ras induced survivin protects against cytotoxic eﬀects
throughout the cell cycle
HeLa cells express high levels of survivin in a cell cycle reg-
ulated manner [11]. Therefore, we chose this well characterised
tumor cell line for our experiments. We determined the ade-
quate concentration of Doxorubicin by MTT-assay. We calcu-
lated an ID50 of 4 lM after 24 h for untreated HeLa cells (data
not shown). The adequate time span of 8 h to induce apoptosis
in untransfected, G1 arrested cells was determined by counting
condensed and fragmented nuclei in a time course experiment.
Apoptosis rate was elevated from initially 5% to approximately
10% within 4 h in the presence of Doxorubicin and increased in
a linear range up to 30% until 8 h (data not shown). The ear-
liest time point to detect cleavage of caspase 3 was 6 h after
Doxorubicin addition. The amount of cleaved caspase 3 in-
creased up to 24 h, whereas at this time point also HeLa cells
treated with mimosine only became apoptotic. Level of procas-
pase 3 slightly decreased after 4 h of Doxorubicin treatment
(Fig. 1a). We transiently overexpressed c-H-ras in HeLa cells
and compared the cytotoxic eﬀects of Doxorubicin in diﬀerent
cell cycle stages by determining apoptosis rates (Fig. 1b).
Arresting cells in diﬀerent cell cycle phases, without any addi-
tional treatment, resulted in an apoptosis rate between 1% and
7%, compared to a basic level of approximately 6% in un-
treated cells (Fig. 1a and data not shown). Doxorubicin treat-
ment of unarrested cells resulted in about 20% apoptosis in
CMVras as well as in control transfected cells. Compared to
untransfected HeLa (Fig. 1a), apoptosis rates were generally
higher in the transfection experiments. This may be an eﬀect
of this additional treatment. In control transfected cells, Doxo-
rubicin treatment of G2/M arrested onces led to an increase of
apoptosis rate of about 10% (Fig. 1b, bars 5 and 6), whereas in
G1 and G1/S arrested cells apoptosis rate increased dramati-
cally to about 50% (Fig. 1b, bars 7 and 8). In contrast, in CMV-
ras transfected cells, apoptosis rate remained at the level of
unarrested cells with evanescent aberrations, remarkably even
in G1 and G1/S arrested cells (Fig. 1b, bars 1–4). Similar results
were obtained using 1 lMStaurosporine (data not shown). Ras
and survivin protein expression was compared in control and
CMVras transfected, arrested cells (Fig. 1c). In control trans-
fected HeLa cells, strongest survivin expression was detected
in G2/M (Fig. 1c, lane 6), whereas expression in G1 and G1/S
phase was severely reduced (Fig. 1c, lanes 7 and 8). Endogenous
ras expression was not observed in control transfected cells
(Fig. 1c, lanes 5–8). In contrast, CMVras transfected cells exhi-
bit high survivin expression in all cell cycle phases, with a
remarkable increase in G1/S (Fig. 1c, lanes 1–4). Taken
together, we found that ectopic expression of c-H-rasVal12 leads
to survivin expression also in G1 and G1/S phase, independent
of its otherwise strict cell cycle regulated expression in G2/M.
This c-H-ras induced survivin expression protects HeLa cells
against cytotoxic eﬀects in all cell cycle phases.3.2. Prevention of drug-mediated apoptosis is a speciﬁc eﬀect due
to survivin expression
To verify the protective eﬀect of survivin expression against
chemotherapeutic substances, we silenced survivin expression
using siRNA. We transfected HeLa cells with siRNA oligos
for survivin mRNA (SRi-2), a scrambled construct (scraSRi)
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Fig. 1. Ras induced survivin protects against cytotoxic eﬀects
throughout the cell cycle. (a) HeLa cells were arrested in G1 for 18 h
and 4 lM Doxorubicin was added for 2, 4, 6, 8, 12 and 24 h,
respectively. Western analysis of a cleaved caspase 3 and procaspase 3
is shown. Actin was used as loading control. Unarrested (unarr.) cells
were used as control. HeLa cells arrested in G1 for 18 + 24 h (G1 arr.
long) are shown in lane 9. (b) HeLa cells were seeded into 24-well
plates and transfected with CMVras or pUC19 as vector control. Four
hours after transfection cells were arrested in G2/M, G1 and G1/S for
24 h. Unarrested cells were used as control. For the last 8 h cells were
treated with Doxorubicin. Cells were ﬁxed and DNA was stained with
DAPI. Per condition, about 1000 cells were counted in randomly
chosen microscopic ﬁelds and apoptosis rate (%) was determined. The
bars represent S.D. (c) Survivin expression is cell cycle independent in
ras expressing, cell cycle arrested HeLa cells. HeLa cells were
transiently transfected with CMVras or pUC19 as vector control.
Cells were treated as described in (a) except addition of Doxorubicin.
Protein lysates were prepared and subjected to immunoblotting with
antibodies against survivin, Ras and actin as loading control.
lane 1 2   3
actin
survivin
v
ec
to
r
co
n
tr
.
SR
i-2
sc
ra
SR
i
treatment
Cell line HeLa
b
16kDa
45kDa
0
10
20
30
40
50
60
treatment: Noc.,  Doxorubicin
a
po
pt
os
is 
ra
te
 (%
)
v
ec
to
r
co
n
tr
.
SR
i-2
sc
ra
SR
i
HeLaa
Fig. 2. Prevention of drug-mediated apoptosis is a speciﬁc eﬀect due to
survivin expression. (a) HeLa cells were seeded into 24-well plates 24 h
before transient transfection with a vector (pUC19) alone or together
with a siRNA construct against survivin mRNA (SRi-2). A scrambled
RNA construct (scraSRi) was used as siRNA control. Four hours after
transfection cells were arrested in G2/M for 24 h. For the last 8 h cells
were treated with Doxorubicin. Cells were ﬁxed and DNA was stained
with DAPI. Per condition, 10 randomly chosen microscopic ﬁelds were
counted and apoptosis rate was determined. The bars represent S.D.
(b) Silencing of survivin expression by SRi-2 was conﬁrmed by
immunoblotting. HeLa cells were transiently transfected with a vector
(lane 1) alone as transfection control or together with SRi-2 (lane 2)
and scraSRi (lane 3), respectively. Twenty-eight hours after transfec-
tion cell lysates were prepared and subjected to immunoblotting with
antibodies against survivin and actin as loading control.
K.W. Sommer et al. / FEBS Letters 581 (2007) 4921–4926 4923as siRNA control [35] and a vector alone as transfection con-
trol. Cells were arrested in G2/M phase, where they express
high levels of survivin (Fig. 1b, lane 6). After treatment with
Doxorubicin the number of apoptotic cells was determined
(Fig. 2a). Apoptosis rate of vector control transfected, G2/M
arrested cells was 20% (Fig. 2a, bar 1). Transfection with
SRi-2 increased the number of apoptotic cells to about 50%
(Fig. 2a, bar 2), whereas apoptosis rate of scraSRi transfected
cells was about 25%. To conﬁrm silencing of survivin mRNA
and consequently protein expression, immunoblot analysis was
performed (Fig. 2b). Survivin protein level of SRi-2 transfected
cells decreased remarkable compared to vector control
(Fig. 2b, lanes 1 and 2). Using scraSRi slightly increased survi-
vin protein level (Fig. 2b, lane 3). Thus, protection against
cytotoxic eﬀects can be correlated with survivin mRNA expres-
sion.
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Fig. 3. Sustained survivin expression is connected to oncogenic,
activated c-H-ras. (a) Western blot analysis of cell cycle arrested c-
H-Ras expressing and non-expressing HeLaDiR-1 subclone. Cells were
arrested in G2/M, G1 and G1/S for 24 h. Unarrested cells (unarr.) were
used as control. Cell lysates were prepared and subjected to immuno-
blotting with antibodies against survivin, Ras and actin as loading
control. (b) Cell cycle distribution of growing and arrested c-H-Ras
expressing and non-expressing HeLaDiR-1 cells. FACS analysis was
performed as control for cell cycle arrest. Viable cells are shown. (c)
Northern blot analysis of growing and cell cycle arrested c-H-Ras
expressing and non-expressing HeLaDiR-1 cells using a probe for
survivin and normalised to 28S rRNA. Cells were treated as described
in (a). Total mRNA was isolated and used for Northern blot analysis.
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activated c-H-ras
To specify the eﬀect of c-H-ras being responsible for sus-
tained survivin expression, we analysed this interdependencetaking the advantage of a HeLa cell line stably expressing a
Dex-inducible, oncogenic c-H-ras. To conﬁrm the eﬀectiveness
of ras-induction by Dex we performed immunoblotting
(Fig. 3a). In induced cells ras was constantly expressed,
whereas it was undetectable in uninduced cells. Survivin
expression was compared at diﬀerent cell cycle phases. Induced
(c-H-ras-on) and non-induced (c-H-ras-oﬀ) HeLaDiR-1 cells
were arrested in G2/M, G1 and in G1/S phase. These treat-
ments only slightly inﬂuenced the viability of cells (as described
in Fig. 1). The eﬃciency was determined by FACS analysis
(Fig. 3b). In unarrested HelaDiR-1 cells expression of c-H-
ras had no eﬀect on cell cycle distribution. Diﬀerences between
c-H-ras-on and -oﬀ cells were found in G2/M and G1 arrested
cells. G1 arrest in c-H-ras-on cells led to a remaining fraction
in G2/M (Fig. 3b, compare bars 3 and 7) whereas block in G2/
M of c-H-ras-oﬀ cells was incomplete (Fig. 3b, compare bars 2
and 6). In spite these leakages, again we found in c-H-ras-oﬀ
cells highest survivin protein expression in G2/M phase
(Fig. 3a, lanes 5–8), whereas in c-H-ras-on cells survivin was
additionally expressed in G1 and G1/S phase (Fig. 3a, lanes
1–4). Interested in the regulatory level of this interdependence,
we investigated the inﬂuence of activated ras on survivin
expression at transcriptional level using Northern blot analy-
sis. Survivin mRNA was upregulated in G1 and G1/S arrested,
c-H-ras-on (Fig. 3c, lanes 1–4), compared to c-H-ras-oﬀ HeLa-
DiR-1 cells (Fig. 3c, lanes 5–8). Thus, decoupling of survivin
from the cell cycle to a sustained expression was shown to be
regulated at transcriptional level via the c-H-ras/survivin axis
in a human cancer cell line.4. Discussion
Survivin overexpression is frequently detected in tumors [11]
and in various tumorderived cell lines, as in HeLa cells
(Fig. 1c) [36]. Here we demonstrate that mutated, constitutive
active c-H-ras reﬂects the missing link between the anti-apop-
totic property of survivin to its (de)regulated expression during
the cell cycle and thus acts at the interface between prolifera-
tion and cell death decision. Cell cycle phase independent, sus-
tained survivin expression driven by activated c-H-ras,
protected HeLa cells against apoptosis induced by the chemo-
therapeutic substance Doxorubicin. Although K-Ras is the
more important ras family member in human tumorigenesis,
we performed our experiments with c-H-Ras to refer to previ-
ous studies, where we analysed a series of c-H-Ras trans-
formed rat cell lines [21].
Endogenous survivin reexpression was described in a series
of human malignancies compared to normal tissues [11,37],
which conﬁrms cancer speciﬁc survivin promoter activity
[38], but no correlation was drawn to oncogenic mutations.
These ﬁndings might support observations of survivin expres-
sion independent of the mitotic index [39]. Survivin was found
to be expressed independently of cell cycle progression after
stimulation by cytokines in hematopeotic cells, i.e. CD34+
stem cells [40]. In a more recent study from the same authors,
they show that interleukin-stimulated survivin expression de-
creased upon inhibition of endogenous ras in these CD34+
cells. Furthermore, in murine Ba/F3 cells overexpression of
activated H-ras was found to upregulate survivin in G0/G1
cells independent of interleukin [20]. Recently published data
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expression. The authors describe that upon stimulation, survi-
vin was upregulated in late G1 and thus responsible for an in-
creased S phase progression during T cell proliferation [31].
These data reﬂect also a physiological role of survivin espe-
cially in hematopoetic cells. In cells of epithelial and mesenchy-
mal origin, cell cycle independent survivin expression was
found in malignancies only. In prostate carcinoma cell lines
survivin was increased in all cell cycle phases by IGF-1 [41].
We demonstrated previously in a c-H-ras transformed, mesen-
chymal cell line that cell cycle dependent survivin expression
was deregulated [21]. In this work the overexpression of onco-
genic c-H-ras in a human carcinoma cell line led to sustained
survivin expression throughout all cell cycle phases. Remark-
ably, transient ras overexpression led to highest survivin levels
in G1/S arrested HeLa cells (Fig. 1c). It was shown that survi-
vin interacts with cyclin-dependent kinases such as Cdk2 and
Cdk4, which are known to regulate G1 to S transition [42]
or that survivin is induced by E2F, a transcriptional regulator
also at G1/S transition [43], respectively. Hence, it should be
reasonable to speculate that, in addition to the here described
activity of mutated c-H-ras in malignant cells, also a physio-
logically activated ras pathway might provide the missing an-
swer to the question how sustained survivin expression could
be driven [44].
Growing evidence has indicated that survivin expression
plays an essential role in drug resistance and that genetic or
pharmacological modulation of survivin expression aﬀects
drug eﬀectiveness in apoptosis induction [6]. We observed in
c-H-ras-transfected HeLa cells a decreased apoptosis rate in
all cell cycle phases after Doxorubicin treatment (Fig. 1b, bars
1–4). Whereas in mock-transfected HeLa cells apoptosis rate
increased dramatically in G1 and G1/S arrested cells
(Fig. 1b, bars 5–8), in correlation with low levels of endoge-
nous survivin (Fig. 1c, lane 5–8). Targeted inhibition of high
survivin level in G2/M arrested HeLa cells by siRNA, led to
increased apoptosis rate after Doxorubicin treatment
(Fig. 2a). Recently it was published that cell cycle independent
survivin expression in prostate carcinoma cells conferred resis-
tance to Flutamide treatment [41]. The authors also concluded
that targeted inhibition of survivin enhances the therapeutic ef-
fects of Flutamide. Their observations also support our data
and the approach that susceptibility to chemotherapeutic
drugs in tumors with sustained and elevated survivin expres-
sion could be improved by pretargeting survivin.
Taken together, we describe an important interdependence
between the oncoprotein ras and survivin as a possible
answer to the outstanding questions how this protein is able
to merge its dual functions, in cell cycle regulation and
in survival pathways. We show a ras-dependent deregulation
of survivin expression that severely impacts survival of
carcinoma cells and their susceptibility to chemotherapeutic
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